-+ 0.00%
-+ 0.00%
-+ 0.00%

Teradyne (TER) Could Be 17% Undervalued On Strong Q2 Earnings Beat

Simply Wall St·08/02/2026 11:18:17
语音播报

Teradyne (TER) is back in focus after its second quarter 2026 earnings report, which featured strong year over year gains in revenue and earnings, along with segment strength in Semiconductor Test and Robotics.

See our latest analysis for Teradyne.

Teradyne's recent results and new third quarter 2026 guidance sit against a sharp share price pullback over the past month, with a 30 day share price return of down 13.96%. However, momentum on a longer view remains strong given the 77.15% year to date share price return and very large 1 year total shareholder return of 253.91%.

If Teradyne's earnings strength has you thinking more broadly about automation, it could be a good moment to scan other robotics and test suppliers using our 36 robotics and automation stocks

Teradyne’s operational story is strong, and the recent pullback sits in sharp contrast to the past year’s very large share price gains. The key issue now is whether that strength is already fully reflected in today’s valuation.

Most Popular Narrative: 16.8% Undervalued

The most widely followed Teradyne narrative sees fair value at $442.20 compared with the last close of $367.69, which places valuation front and center for investors.

The analysts have a consensus price target of $442.2 for Teradyne based on their expectations of its future earnings growth, profit margins and other risk factors.

In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $7.3 billion, earnings will come to $2.2 billion, and it would be trading on a PE ratio of 41.4x, assuming you use a discount rate of 11.0%.

Read the complete narrative.

Want to see what sits behind that higher fair value for Teradyne? The narrative leans on faster growth, higher margins, and a richer earnings multiple. The exact mix of those three levers might surprise you.

The fair value estimate in this narrative uses a discount rate of 10.99%, so you can compare its assumptions directly with your own required return. The result labels Teradyne as undervalued relative to $442.20, yet the gap depends entirely on whether you agree with the forecast path for revenue, earnings, and margins that analysts have built into their models.

Result: Fair Value of $442.20 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, Teradyne’s narrative still faces real pressure points, including weaker robotics revenue and ongoing tariff and trade policy uncertainty that could challenge those longer term assumptions.

Find out about the key risks to this Teradyne narrative.

Another View On Teradyne’s Valuation

The narrative fair value of $442.20 contrasts with the Simply Wall St DCF model, which puts Teradyne at $241.79 based on projected future cash flows. On that basis, the current $367.69 share price screens as expensive rather than undervalued. Which framework do you find more convincing?

For readers who want to see how the detailed cash flow assumptions drive that gap, Look into how the SWS DCF model arrives at its fair value.

TER Discounted Cash Flow as at Aug 2026
TER Discounted Cash Flow as at Aug 2026

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Teradyne for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 55 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

Teradyne's mix of strong recent performance, a sharp pullback in the share price and split valuation signals makes this a nuanced story. Act while the data and sentiment are fresh, and weigh the trade off between optimism and concern for yourself with the 5 key rewards and 2 important warning signs

Looking for more investment ideas beyond Teradyne?

If Teradyne has sharpened your focus, do not stop here. Broader opportunities across the market could suit your goals just as well or even better.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.